primary endpoitn was 'composite' so FDA granted approval based on primary composite endpoints.

FDA doesn't consider seriously secondary and/or exploratory outcomes if primary endpoint doesn't meet.

Empagliflozin is approved for pEF which doesn't really have treatments as opposed rEF which has many treatments. So, pEF is indeed a good population to go after (for RVX).

But, currently RVX is being tiraled in population with diabetes not heart failure. These are 2 diff. populations.